Evaluation of Vav3.1 as prognostic marker in endometrial cancer

ConclusionsOur study shows that Vav3.1 is not suited as a marker of cancer progression and/or treatment response in endometrial cancer. Feasibility and potential benefit of targeting Vav3.1 in endometrial cancer needs to be evaluated in future studies, proceeding from its clear, roughly ten-fold, induction in the malignant endometrium.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research